SSRI        MARKETING INFORMATION 
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Marketing information: strengths and weaknesses

Strengths:

  • Proven efficacy as acute therapy and maintenance therapy in patients with unipolar depression.
  • Generally well tolerated.
  • Few drug–drug interactions.

Weaknesses:

  • Data on acute therapy are limited and there are no data on controlled maintenance therapy in bipolar depression.
  • May cause switching and/or cycle acceleration.


  
 Switching support data
- Mood stabilizers: antidepressant-induced switching
- Antidepressant-associated mania and hospitalization
- Switch rates with 2nd-generation antidepressants
- Antidepressant-induced switch rates
- Paroxetine and switching
- SSRI combined with valproate or lithium
- Switch rates in clinical practice
- Risk factors for antidepressant-induced mania
- SSRIs and switching in young bipolar patients

General links
* British National Formulary
* PDR.net: Interactive Healthcare for Medical and Drug Information
* European Agency for the Evaluation of Medicinal Products

 * = Internet link
 
home help sitemap acronyms help sitemap home